Metabolic Syndrome Clinical Trial
Official title:
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Hyperlipidemia and atherosclerosis lead to cardiovascular diseases and are an indirect cause
of increased death rate in the general population. This association is still more evident in
specific subpopulations, like patients with advanced chronic kidney disease (CKD),
especially hemodialysis (HD) patients, due to a higher prevalence of lipid disturbances and
atherosclerosis compared to the general population. Cardiovascular events in CKD patients
are frequently associated with traditional risk factors, including diabetes, male sex,
hypertension, dyslipidemia and advanced age. However, these factors failed to fully account
for the increased risk of cardiovascular events in CKD. The efforts are made to identify new
risk factors that contribute to the development of atherosclerosis and participate in causes
of cardiovascular death. In 2003, there were identified peptides designated salusin-alpha
and salusin-beta. Development of atherosclerosis may be suppressed by salusin-alpha.
Salusin-alpha may have a lipid lowering effect, similar to that of statins.
The purpose of this study is to investigate whether 1) salusin-alpha is associated with
lipid metabolism of HD patients (without or with metabolic syndrome or type 2 diabetes
mellitus), similarly or not like in healthy or obese subjects; 2) treatment with
atorvastatin and its effects are associated with changes in plasma salusin-alpha
concentration, if so - whether it is dependent on the direct influence of atorvastatin on
salusin-alpha or associated with a decrease in serum lipid level; 3) salusin-alpha may
predict mortality in HD patients.
Purpose I, step 1. To investigate whether plasma salusin-alpha is associated with lipid and
lipid-related abnormalities in hemodialysis (HD) patients, plasma salusin-alpha
concentration, expression of receptor CD36 on macrophages, serum lipid parameters,
anthropometric and laboratory indices of nutrition and biomarkers of inflammation will be
cross-sectionally analyzed. In chronic kidney disease (CKD) patients there is a close
association between atherosclerosis (A), malnutrition (M) and inflammation (I), known as MIA
syndrome, so interactions between all these parameters will be obviously present and should
be taken into account. In addition, homeostasis model assessment of insulin resistance
(HOMA-IR) will be applied as insulin resistance is a metabolic abnormality occurring in
advanced CKD, in metabolic syndrome shown in about 50% of HD patients and diabetic mellitus
(DM), being a cause of CKD in approximately 40% of cases. Results of correlations and
associations shown in HD patients will be compared with those of healthy controls and obese
persons with normal renal function for evaluation of salusin-alpha relationships under
different metabolic conditions, which may exert not uniform influence.
Study populations:
HD patients (n = 200) Obese persons (n = 50) Controls (n = 60)
Data collection:
Medical history (with special attention for demographics - age, gender, cause of CKD, renal
replacement therapy vintage, changes in body weight, habits and data required for inclusion
and exclusion criteria.
Physical examination (with special attention for skin abnormalities related to lipid
disturbances and blood pressure).
Anthropometric indices:
- directly measured: height, body weight, hip and waist circumferences, midarm
circumference (MAC), triceps skin fold thickness (TSF)
- calculated or estimated: hip to waist ratio (WHiR), height to waist ratio (WHeR), body
mass index (BMI), in HD patients - dry body weight (DBW) Laboratory parameters
- Apolipoprotein A1 (APOA1)
- Apolipoprotein B (APO B)
- Cholesterol - total
- Cholesterol HDL
- Cholesterol LDL directly measured
- CD36
- Free fatty acids (FDA)
- High sensitivity C-reactive protein (hsCRP)
- HOMA-IR
- Interleukin 6 (IL-6)
- L-carnitine
- Lipase
- Lipoprotein(a)
- Salusin-alpha
- Triglycerides
- Basic serum biochemistry
Purpose I, step 2. HD patients suffering from type 2DM or having metabolic syndrome (MeS)
are at risk of more severe lipid abnormalities than the remaining ones. Data collected in
Step 1 will be helpful in diagnosis of MeS in the examined HD patients. The investigators
expect that also in controls they will find persons with abnormal serum lipid profile.
Differences inside these both groups may influence plasma salusin-alpha levels and the
examined associations. Thereby, the following groups will be analyzed separately and
compared to each other:
For HD patients:
- group with MeS and with type 2 DM
- group only with MeS
- group only with type 2 DM
- group without MeS and without DM
For controls:
- group without detected serum lipid abnormalities
- group with detected serum lipid abnormalities
Validation of correlations/associations found in the cross-sectional study will be done in
the prospective studies (Purpose II) and at the final analysis (Purpose III).
Purpose II. The treatment with atorvastatin lowers serum LDL cholesterol in HD patients.
Using this statin during the study, the investigators can observe dynamic changes in serum
LDL cholesterol in HD patients with known plasma salusin-alpha concentration before
atorvastatin medication. With repeated salusin-alpha measurements during continued
atorvastatin treatment the investigators can follow concomitantly occurring (or not
occurring) changes in plasma salusin-alpha concentrations, which can be related to
atorvastatin directly or to its LDL cholesterol lowering effect. To elucidate this aspect,
the investigators plan to examine hyperlipidemic HD patients treated with a prescribed diet
and increased physical activity as well as obese persons (not taking lipid lowering
medication) during weight lowering therapy, which usually decreases lipidemia. Results of
these persons may give the answer whether a decrease in lipidemia without pharmaceutical
medication leads (may be also leads) to changes in plasma salusin-alpha concentration.
The prospective study is planned in two groups of persons:
HD patients, participating in Step 1 (n = 200), Obese persons, participating in Step 1 (n =
50).
Purpose III. Annual mortality rate in HD patients is 10 - 15%. LDL cholesterol and total
cholesterol are predictors of mortality in end-stage renal disease patients. If
salusin-alpha is associated with lipid abnormalities, it is a reasonable to check whether
this peptide may be a predictor of mortality in HD patients. To investigate this aspect the
investigators plan to perform the analysis of HD patients outcome after two years from the
first salusin-alpha determination and to check whether there is any association between
plasma salusin-alpha concentration and death from cardiovascular events and all cause death.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |